Silence Therapeutics plc has made two key executive appointments.

The London MedTech, listed on New York’s Nasdaq market, aims to ‘silence’ diseases through precision engineered medicines. It delisted from London’s AIM market in 2021 after winning backing from a major US healthcare fund.

Marie Wikström Lindholm, previously senior vice president, head of molecular design, has been promoted to the position of chief scientific officer.

Curtis Rambaran (below), previously vice president, head of clinical science, has been promoted to chief medical officer.

Curtis Rambaran, MD, Chief Medical Officer at Silence Therapeutics plc

“I want to congratulate Curtis and Marie on their well-deserved promotions,” said Steven Romano, head of research and development at Silence. “Both have been instrumental to our clinical and scientific successes to date. 

“Curtis’ broad experience leading successful early and late-stage development programs combined with his background in cardiovascular medicine will be invaluable to Silence’s next phase of growth. 

“With our expanding mRNAi GOLD™ platform programs and commitment to advancing scientific research, I am also looking forward to continuing to collaborate closely with Marie. Her extensive work in oligonucleotide therapeutics is impressive and we are very fortunate to have her leading our efforts to innovate and further expand our footprint as a global siRNA leader.”